BioSpace News Archive

Draupnir Bio, a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, announces the appointment of Andrew Hotchkiss as Chief Executive Officer.

Editas Medicine, Inc., a leading genome editing company, announced that centers are now enrolling the first of two planned pediatric cohorts in the Phase 1/2 BRILLIANCE clinical trial of EDIT-101 following the Independent Data Monitoring Committee endorsement to proceed.

Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for the treatment of cancer, rare conditions, and novel coronaviruses, announced that it has submitted an Investigational New Drug application to India’s Central Drugs Standard Control Organization to evaluate its investigational drug, Silmitasertib, for the treatment of COVID-19.

Evogene Ltd. announced today that its Board of Directors has resolved to appoint Ms. Sarit Firon to serve as Chairperson of the Board

Vita Therapeutics today announced the completion of an oversubscribed $32 million Series A.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the U.S. launch of expanded parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses.

Orum today announced the close of a $84 million Series B financing.

Genomic Testing Cooperative, LCA announced that the New York State Clinical Evaluation Program has completed their evaluation and approved all GTC’s Next Generation Sequencing profiling tests for hematologic neoplasms and solid tumors.

Promega Corporation. The 2021 Corporate Responsibility Report, released today, features new 2030 Environmental Improvement Goals alongside stories of how Promega is supporting researchers, employees and communities during the COVID-19 pandemic.

Clovis Oncology, Inc. announced today that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286.